Association between rim enhancement of breast cancer on dynamic contrast-enhanced MRI and patient outcome: impact of subtype

Breast Cancer Research and Treatment

Volumn 148, Issue 3, 2014, Pages 541-551

  Schmitz, Alexander M Th ^a   Loo, Claudette E ^b   Wesseling, Jelle ^b   Pijnappel, Ruud M ^a   Gilhuijs, Kenneth G A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Breast cancer subtype; DCE MRI; Rim enhancement

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST CANCER RIM ENHANCEMENT; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DYNAMIC CONTRAST ENHANCED MRI; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PREOPERATIVE EVALUATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; AGED; CARCINOGENESIS; CLINICAL TRIAL; GENETICS; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; TUMOR RECURRENCE;

ADULT; AGED; CARCINOGENESIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84911998473     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3170-9     Document Type: Article

References (30)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
3. Szabo BK, Aspelin P, Kristoffersen WM, Tot T, Bone B (2003) Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 13:2425–2435
4. Chang YW, Kwon KH, Choi DL, Lee DW, Lee MH et al (2009) Magnetic resonance imaging of breast cancer and correlation with prognostic factors. Acta Radiol 50:990–998
5. Narisada H, Aoki T, Sasaguri T, Hashimoto H, Konishi T et al (2006) Correlation between numeric gadolinium-enhanced dynamic MRI ratios and prognostic factors and histologic type of breast carcinoma. AJR Am J Roentgenol 187:297–306
6. Teifke A, Behr O, Schmidt M, Victor A, Vomweg TW et al (2006) Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 239:351–360
7. Matsubayashi R, Matsuo Y, Edakuni G, Satoh T, Tokunaga O et al (2000) Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841–848
8. Lee SH, Cho N, Kim SJ, Cha JH, Cho KS et al (2008) Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol 9:10–18
9. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S et al (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649
10. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S et al (1997) Patterns of peripheral enhancement in breast masses: correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. J Comput Assist Tomogr 21:421–430
11. Elshof LE, Rutgers EJ, Deurloo EE, Loo CE, Wesseling J et al (2010) A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Res Treat 124:707–715
12. American College of Radiology (ACR) (2003) Breast imaging reporting and data system (BI-RADS Atlas). American College of Radiology, Reston, VA
13. Deurloo EE, Tanis PJ, Gilhuijs KG, Muller SH, Kroger R et al (2003) Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 39:1068–1073
14. Egan RL (1982) Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10 year survival. Cancer 49:1123–1130
15. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153–3158
16. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132
17. Jiang L, Zhou Y, Wang Z, Lu X, Chen M et al (2013) Is there different correlation with prognostic factors between “non-mass” and “mass” type invasive ductal breast cancers? Eur J Radiol 82:1404–1409
18. Houssami N, Turner R, Macaskill P, Turnbull LW, McCready DR et al (2014) An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol 32:392–401
19. Pengel KE, Loo CE, Wesseling J, Pijnappel RM, Rutgers EJ et al (2014) Avoiding preoperative breast MRI when conventional imaging is sufficient to stage patients eligible for breast conserving therapy. Eur J Radiol 83:273–278
20. Hudis CA (2007) Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 357:39–51
21. Cleator S, Heller W, Coombes RC (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244
22. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728
23. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434
24. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281
25. Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY et al (2003) The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 81:137–147
26. Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Tsubono Y et al (1998) Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 49:195–208
27. Colpaert C, Vermeulen P, van BP, Goovaerts G, Weyler J et al (2001) Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 39:416–425
28. Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van dA I et al (2008) Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 14:2944–2952
29. Carlson DJ, Keall PJ, Loo BW Jr, Chen ZJ, Brown JM (2011) Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia. Int J Radiat Oncol Biol Phys 79:1188–1195
30. Ferrara N (2004) Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl 1):2–10